Close Menu
Innovation Village | Technology, Product Reviews, Business
    Facebook X (Twitter) Instagram
    Friday, January 30
    • About us
      • Authors
    • Contact us
    • Privacy policy
    • Terms of use
    • Advertise
    • Newsletter
    • Post a Job
    • Partners
    Facebook X (Twitter) LinkedIn YouTube WhatsApp
    Innovation Village | Technology, Product Reviews, Business
    • Home
    • Innovation
      • Products
      • Technology
      • Internet of Things
    • Business
      • Agritech
      • Fintech
      • Healthtech
      • Investments
        • Cryptocurrency
      • People
      • Startups
      • Women In Tech
    • Media
      • Entertainment
      • Gaming
    • Reviews
      • Gadgets
      • Apps
      • How To
    • Giveaways
    • Jobs
    Innovation Village | Technology, Product Reviews, Business
    You are at:Home»Acquisitions»Adenia Partners marks Egypt entry with majority stake in Parkville Pharmaceuticals
    Stéphane Bacquaert, Managing Partner of Adenia Partners

    Adenia Partners marks Egypt entry with majority stake in Parkville Pharmaceuticals

    0
    By Tapiwa Matthew Mutisi on January 30, 2026 Acquisitions, Business, Deals, Health, News

    In a significant move within the North African healthcare landscape, the private equity firm Adenia Partners has signed definitive agreements to acquire a majority interest in Parkville Pharmaceuticals. The stake is being acquired from Admaius Capital Partners, with the transaction involving a partnership with Parkville’s original leadership, including Chairman Sherif Bassiouny and CEO Mahmoud Farrag.

    Headquartered in Cairo, Parkville Pharmaceuticals established itself as a resilient player in Egypt’s diversified healthcare market. While the financial specifics of the deal remain confidential, the transaction is currently progressing through customary regulatory approvals and closing conditions.

    A Diversified Healthcare Portfolio

    Since its founding in 2008, Parkville has expanded far beyond traditional medicine. The company operates across three high-growth verticals:

    • Pharmaceuticals: Development and distribution of therapeutic lines.
    • Cosmeceuticals: Specialized skincare, haircare, and personal care products (including deodorants).
    • Nutraceuticals: Wellness and nutritional supplement products.

    This multi-sector approach has allowed Parkville to capture a broad consumer base, ranging from clinical patients to retail wellness shoppers.

    This acquisition is a landmark for Adenia Partners, marking their first investment in Egypt. The move signals a strong belief in the country’s long-term economic fundamentals and its ability to produce regional market leaders.

    Stéphane Bacquaert, Managing Partner of Adenia Partners, highlighted the scalability of the business:

    We are delighted our first acquisition in Egypt is into one of the region’s fastest growing businesses. We see tremendous potential in Parkville’s mission to expand access to affordable, high-quality health and personal care products.

    Heba Hakky, Principal at Adenia, added that the investment reflects a conviction in the strength of local champions and the next phase of growth for the Egyptian pharmaceutical sector.

    Under the leadership of Dr. Mahmoud Farrag, Parkville has undergone a significant transformation over the last two years. The partnership with Adenia is intended to fuel a more aggressive expansion strategy:

    1. Product Diversification: Expanding the current offering across health and personal care categories.
    2. Digital & Commercial Strengthening: Enhancing the company’s ability to reach consumers through modern retail and digital channels.
    3. Regional Growth: Using Egypt as a springboard to scale operations across the Middle East and Africa (MEA).

    Dr. Farrag noted that the ambition is now to position Parkville as a “Middle East and Africa champion,” delivering sustainable value for investors while maintaining an empowering environment for its workforce.

    The transaction also marks a successful outcome for Admaius Capital Partners, who partnered with Parkville during a critical two-year period of value creation. The sale demonstrates a healthy “deal flow” within the Egyptian private equity space, showing that international firms can successfully scale and exit high-quality local assets.

    Admaius Capital Partners exits investment in Parkville Pharmaceuticals

    Related

    Acquisition Adenia Partners Admaius Capital Partners Africa Business Eqypt Funding Healthcare Investments Parkville Pharmaceuticals pharmaceuticals
    Share. Facebook Twitter Pinterest LinkedIn Email
    Tapiwa Matthew Mutisi
    • Facebook
    • X (Twitter)
    • LinkedIn

    Tapiwa Matthew Mutisi has been covering blockchain technology, intelligent technologies, cryptocurrency, cybersecurity, telecommunications technology, sustainability, autonomous vehicles, and other topics for Innovation Village since 2017. In the years since, he has published over 6,000 articles — a mix of breaking news, reviews, helpful how-tos, industry analysis, and more. | Open DM on Twitter @TapiwaMutisi

    Related Posts

    Adenia and Proparco exit OCS Group to Retail Holding and Amethis consortium

    Sam Altman’s OpenAI Confirms GPT-4o Shutdown as GPT-5.2 Becomes Default Model

    Tellef Thorleifsson to step down as Norfund CEO following period of historic growth

    Leave A Reply Cancel Reply

    You must be logged in to post a comment.

    Copyright ©, 2013-2024 Innovation-Village.com. All Rights Reserved

    Type above and press Enter to search. Press Esc to cancel.